JP2024520898A5 - - Google Patents
Info
- Publication number
- JP2024520898A5 JP2024520898A5 JP2023569779A JP2023569779A JP2024520898A5 JP 2024520898 A5 JP2024520898 A5 JP 2024520898A5 JP 2023569779 A JP2023569779 A JP 2023569779A JP 2023569779 A JP2023569779 A JP 2023569779A JP 2024520898 A5 JP2024520898 A5 JP 2024520898A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187344P | 2021-05-11 | 2021-05-11 | |
| US63/187,344 | 2021-05-11 | ||
| PCT/US2022/072247 WO2022241430A1 (en) | 2021-05-11 | 2022-05-11 | Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024520898A JP2024520898A (ja) | 2024-05-27 |
| JP2024520898A5 true JP2024520898A5 (https=) | 2025-05-19 |
| JPWO2022241430A5 JPWO2022241430A5 (https=) | 2025-05-19 |
Family
ID=82399377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569779A Pending JP2024520898A (ja) | 2021-05-11 | 2022-05-11 | 再発性及び／又は難治性多発性骨髄腫の治療をモニタリングするための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220373550A1 (https=) |
| EP (1) | EP4337962A1 (https=) |
| JP (1) | JP2024520898A (https=) |
| KR (1) | KR20240005919A (https=) |
| CN (1) | CN117295949A (https=) |
| AU (1) | AU2022273326A1 (https=) |
| CA (1) | CA3219969A1 (https=) |
| MX (1) | MX2023013412A (https=) |
| TW (1) | TW202309522A (https=) |
| WO (1) | WO2022241430A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| IL312503A (en) | 2021-11-03 | 2024-07-01 | Janssen Biotech Inc | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
| WO2024168192A1 (en) * | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| CN121358492A (zh) * | 2023-04-19 | 2026-01-16 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US10072088B2 (en) | 2015-08-17 | 2018-09-11 | Janssen Pharmaceutica, Nv | Anti-BCMA antibodies and uses thereof |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| EP4282877A3 (en) | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN112955748A (zh) * | 2018-10-31 | 2021-06-11 | 葛兰素史密斯克莱知识产权发展有限公司 | 治疗癌症的方法 |
| AU2020377930A1 (en) * | 2019-11-05 | 2022-05-19 | Bristol-Myers Squibb Company | Uses of anti-BCMA chimeric antigen receptors |
-
2022
- 2022-05-10 TW TW111117430A patent/TW202309522A/zh unknown
- 2022-05-11 WO PCT/US2022/072247 patent/WO2022241430A1/en not_active Ceased
- 2022-05-11 KR KR1020237042423A patent/KR20240005919A/ko active Pending
- 2022-05-11 CN CN202280034423.8A patent/CN117295949A/zh active Pending
- 2022-05-11 US US17/742,076 patent/US20220373550A1/en not_active Abandoned
- 2022-05-11 EP EP22737692.8A patent/EP4337962A1/en active Pending
- 2022-05-11 CA CA3219969A patent/CA3219969A1/en active Pending
- 2022-05-11 AU AU2022273326A patent/AU2022273326A1/en not_active Abandoned
- 2022-05-11 JP JP2023569779A patent/JP2024520898A/ja active Pending
- 2022-05-11 MX MX2023013412A patent/MX2023013412A/es unknown
-
2025
- 2025-07-25 US US19/281,154 patent/US20250362298A1/en active Pending